Research programme: antigen presenting cell-based therapeutics - NexImmuneAlternative Names: AIM 101; AIM 102; AIM 103; AIM 104; AIM ACT
Latest Information Update: 21 Jul 2015
At a glance
- Originator NexImmune
- Class Antineoplastics; T lymphocyte cell therapies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
- Research Autoimmune disorders; Infections
Most Recent Events
- 21 Jul 2015 Antigen presenting cell-based therapeutics are covered by patent protection in USA (NexImmune website, July 2015)